Table 2.
Statistical comparison between fusion-driven and point mutation-driven pediatric PTCs.
| Fusion n = 48 |
Mutation n = 83 |
Wild-Type n = 32 |
p-Value | ||
|---|---|---|---|---|---|
| Age | |||||
| median, range | 14, 8–18 | 17, 8–18 | 16, 9–18 | < 0.0001 | |
| <15-year-old | 27 (56.3%) | 21 (25.3%) | 13 (40.6%) | 0.0018 | |
| ≥15-year-old | 21 (43.7%) | 62 (74.7%) | 19 (59.3%) | ||
| Sex | |||||
| Female | 34 (70.8%) | 59 (71.1%) | 23 (71.9%) | 0.9947 | |
| Male | 14 (29.2%) | 24 (28.9%) | 9 (28.1%) | ||
| Tumor size [cm] | |||||
| mean (SD) | 2.6 (1.2) | 2.1 (1.3) | 2.3 (1.5) | 0.0200 | |
| PTC variant | |||||
| C-PTC | 32 (66.7%) | 51 (61.4%) | 16 (50.0%) | 0.0955 | |
| FV-PTC | 8 (16.7%) | 17 (20.5%) | 9 (28.1%) | ||
| SV-PTC | 5 (10.4%) | 2 (2.4%) | 2 (6.2%) | ||
| TCV-PTC | 0 | 6 (7.2%) | 1 (3.1%) | ||
| DSV-PTC | 2 (4.2%) | 1 (1.2%) | 1 (3.1%) | ||
| Other a | 1 (2.1%) | 1 (1.2%) | 0 | ||
| NIFTP b | 0 | 5 (6.0%) | 3 (9.4%) | ||
| Tumor invasiveness | |||||
| Totally encapsulated | 0 | 6 (7.7%) | 8 (27.6%) | 0.0003 | |
| Encapsulated with tumor capsule invasion | 3 (6.4%) | 10 (12.8%) | 7 (24.1%) | ||
| Infiltration of thyroid parenchyma | 44 (93.6%) | 62 (79.5%) | 14 (48.3%) | ||
| Extrathyroidal extension | |||||
| Present c | 24 (51.1%) | 21 (26.9%) | 3 (10.3%) | 0.0005 | |
| Absent | 23 (48.9%) | 57 (73.1%) | 26 (89.7%) | ||
| Multifocality | |||||
| Present | 27 (57.4%) | 33 (42.3%) | 9 (31.0%) | 0.0652 | |
| Absent | 20 (42.6%) | 45 (57.7%) | 20 (69.0%) | ||
| Lymphovascular invasion | |||||
| Present | 31 (66.0%) | 29 (37.2%) | 5 (17.2%) | < 0.0001 | |
| Absent | 16 (34.0%) | 49 (62.8%) | 24 (82.8%) | ||
| Tumor stage d | |||||
| T1a | 2 (4.2%) | 14 (18.0%) | 4 (13.8%) | 0.0783 | |
| T1b | 17 (36.2%) | 37 (47.4%) | 14 (48.3%) | ||
| T2 | 20 (42.6%) | 17 (21.8%) | 8 (27.6%) | ||
| T3a | 7 (14.9%) | 10 (12.8%) | 3 (10.3%) | ||
| T4a | 1 (2.1%) | 0 | 0 | ||
| Lymph node metastasis | |||||
| N0 | 7 (14.9%) | 10 (12.8%) | 5 (17.2%) | 0.0489 | |
| N1a | 11 (23.4%) | 18 (23.1%) | 6 (20.7%) | ||
| N1b | 18 (38.3%) | 6 (7.7%) | 3 (10.3%) | ||
| NA | 11 (23.4%) | 44 (56.4%) | 15 (51.7%) | ||
Statistically significant comparisons are reported in bold in the “p-value”column. Abbreviations: SD, standard deviation; PTC, papillary thyroid carcinoma; C-PTC, classical papillary thyroid carcinoma; FV-PTC, follicular variant papillary thyroid carcinoma; SV-PTC, solid variant papillary thyroid carcinoma; TCV-PTC, tall cell variant papillary thyroid carcinoma; DSV-PTC, diffuse sclerosing variant papillary thyroid carcinoma; NIFTP, noninvasive follicular neoplasm with papillary-like nuclear features; NA, not available. a Includes one Hürthle cell PTC and one PTC metastasis without primary tumor. b Excluded from statistical comparisons involving clinico-pathological features. c Minimal and gross extrathyroidal extension considered together for statistical analysis. d T1a plus T1b and T3a plus T4a considered as unique categories for statistical analysis.